52 results about "Disease irritable bowel" patented technology

Method and system to provide therapy for obesity and gastrointestinal disorders such as FGIDs, gastroparesis, gastro-esophageal reflex disease (GERD), pancreatitis and ileus comprises vagal blocking and / or vagal stimulation. Vagal blocking may be in the afferent or efferent direction, and may be with or without stimulation pulses. Blocking may be provided by one of a number of different electrical blocking techniques. Electrical signals may be provided with an external stimulator in conjunction with an implanted stimulus-receiver, or an implanted stimulus-receiver comprising a high value capacitor for temporary power source. In one embodiment, the external stimulator may comprise an optional telemetry unit. The addition of the telemetry unit to the external stimulator provides the ability to remotely interrogate and change stimulation programs over a wide area network, as well as other networking capabilities,

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

The present invention relates to a method of treatment of cachexia in a subject in need of treatment. More specifically, the present invention relates to the use of retinoid compounds that act on retinoid X receptors (RXRs) for the treatment of cachexia in a subject in need of treatment. The cachexia is associated with, in other words a complication of, a primary disease, condition or disorder. Primary diseases, conditions and disorders include, but are not limited to, cancer, AIDS, liver cirrhosis, diabetes mellitus, chronic renal failure, chronic obstructive pulmonary disease, chronic cardiac failure, immune system diseases (e.g., rheumatoid arthritis and systemic lupus erythematosus), tuberculosis, cystic fibrosis, gastrointestinal disorders (e.g., irritable bowel syndrome and inflammatory bowel disease), Parkinson's disease, anorexia nervosa, dementia, major depression, an aged condition and sarcopenia.

Compounds of Formula (I): or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

The invention provides a method of regulating water and mucin secretions and fluid transport in the gastrointestinal tract. The invention also provides a method for treating a gastrointestinal disease in which the mucosal barrier of the gastrointestinal system is impaired. The invention additionally provides a method for correcting disorders of fluid secretion or absorption in the gastrointestinal system. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor agonist, in an amount effective to regulate water and mucin secretions or to correct abnormal fluid transport in the gastrointestinal tract. The pharmaceutical composition used in this invention comprises a P2Y purinergic receptor agonist such as uridine 5'-diphosphate (UDP), uridine 5'-triphosphate (UTP), cytidine 5'-diphosphate (CDP), cytidine 5'-triphosphate (CTP), adenosine 5'-diphosphate (ADP), adenosine 5'-triphosphate (ATP), and their analogs; and dinucleotide polyphosphate compounds of general Formula (IV). Said compound is prepared in an oral form, an injectable form, or a suppository form, and administered to a patient.

The present invention relates to a therapeutic agent for irritable bowel syndrome of diarrhea type, ulcerative colitis, visceral pain or abdominal pain, which contains a compound of the following formula and which has 5-HT7 receptor antagonistic effect or an analogue thereof; and this therapeutic agent has an excellent therapeutic effect and a high safety:

The invention relates to methods and compositions for the treatment of irritable bowel syndrome (IBS) and other functional gastrointestinal disorders. The methods of the invention involve the administration, in a delayed-release capsule or tablet containing a mixture of peppermint oil and chlorophyll. Other ingredients that may also be effective treatments may be included. This method may be useful as a new and safer treatment for IBS and other functional gastrointestinal disorders. The action of the peppermint oil is effective as a modulator of gastrointestinal motility and sensation. Chlorophyll may improve bowel activity by stimulation of secretion and motility. This is the first description of this unique mixture of these natural products for the treatment of gastrointestinal conditions.

The present invention describes novel nitrosated and / or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and / or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.

The invention discloses a veterinary drug for preventing livestock bowel diseases, a preparation method of the drug, and feed. The veterinary drug contains active ingredients which are prepared from purslane, humifuse euphorbia herb, plantain herb, acalypha australis and liquorice. The veterinary drug provided by the invention has the effects of clearing away heat and toxic materials, eliminating dampness to stop dysentery and astringing to stop bleeding, can be effectively used for preventing the livestock bowel diseases such as swine transmissible gastroenteritis, piglet diarrhea, swine dysentery, chicken salmonellosis, chicken colibacillosis and chicken stphyoococcl disease, and has the advantages of an extensive material source, safety, environment-friendliness, a simple preparation process, low production cost and the like.

The invention relates to a Chinese medicinal composition for treating gastrointestinal tract diseases, which is prepared from the following raw materials (by weight ratio): banksia rose, linaloe, bitter orange, magnolia bark each 2-20 parts, Chinese date 10-60 parts, musk 0.1-0.8 part, defatted powder of croton seed 1-10 parts, sandalwood 1-10 parts, rheum officinale 1-10 parts, rhizome of Sichuan lovage 1-10 parts and cinnabar 1-10 parts.

The invention discloses a goose fermented feed and a producing method thereof. The producing method comprises the steps of: synthesizing corn, soy bean meal, wheat bran, wheat middling, rapeseed meal, pomace, trace elements, vitamins, table salt and beneficial microbial flora; removing impurities according to a rational proportion; grinding the materials into 80-100 meshes rough powders and mixing the powders; mixing mechanically and uniformly and cooling to pelletize; and sealing by plastic bag film, and packaging for warehousing, selling or standby application. Odor in the goose tongue can be changed and environment can be purified by using the goose fermented feed. Meanwhile, the goose fermented feed, disclosed by the invention, has the advantages of saving cost, being low in price, changing the waste into wealth to bring about obvious economic benefit as the raw materials of the goose fermented feed is extremely easy to purchase, being natural, green, ecological and environment-friendly, and having obvious function on preventing goose bowel diseases.

Methods of determining gastro-intestinal conditions by performing a succession of breath tests or others tests, particularly for determining the gastric emptying or gastric accomodation condition of a subject. Methods of performing successive gastric emptying tests with different test meals are also presented, enabling the gastric accommodation to be determined. The effects of different test means on the results is presented. Novel substrates for use in such tests are suggested, including the use of micro-encapsulation. Breath tests for the detection of bacterial overgrowth, lactose intolerance and combinations thereof are presented.

The present invention relates to the field of methods and apparatus for the determination of various conditions of gastric and gastro-intestinal malfunction, especially those performed by means of breath tests.

The present invention relates to novel imidazole compounds having a positive allosteric GABAB receptor (CUR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).

Compounds of Formula (I):or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

Provided herein are methods, compositions, and kits for the treatment of an enteric nervous system disorder. Such methods may comprise administering to a subject an effective amount of a phenothiazine compound, a peripherally restricted dopamine decarboxylase inhibitor, and / or a peripherally restricted dopamine D2 receptor antagonist that does not substantially inhibit hERG channels.

A method for the treatment and / or prophylaxis of disorders of the gastrointestinal system, other disorders selected from post exercise recovery, heat stress, vasovagal states, sleep disorders and fluid loss, and for the maintenance of blood sugar level homeostasis, comprising orally administering to said patient an admixture of vitamins and minerals formulated to have a pH greater than or equal to 5.0 in aqueous solution.

The present invention provides compositions and methods for preventing and treating gastrointestinal disorders by administering to a subject an effective amount of secretin either alone or in combination with an effective amount of oxytocin. The invention also provides compositions and methods for preventing and treating central nervous system disorders by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. The invention further provides compositions and methods for treating and preventing a variety of autoimmune diseases by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. Additionally, the invention provides compositions and methods for preventing and treating pain by administering to a subject using a combination of an effective amount of secretin and an effective amount of oxytocin. The invention also provides kits for use in treating and / or preventing gastrointestinal disorders, central nervous system disorders, autoimmune diseases and pain comprising a combination of secretin and oxytocin.

Embodiments are directed to compositions and related methods for treating gastrointestinal disorders with a granulated mesalamine formulation. In some embodiments, the gastrointestinal disorder being treated is irritable bowel syndrome (IBS). In some embodiments, the gastrointestinal disorder being treated is diarrhea-predominant IBS (d-IBS).

The invention discloses application of carboxyl aminotriazole or pharmaceutically acceptable salts of the carboxyl aminotriazole in the preparation of medicaments for preventing and / or treating neurodegenerative diseases, amyotrophic lateral sclerosis and inflammatory bowel diseases and also relates to the medicament packages or kits comprising the medicaments.

Compounds of Formula (I):or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

Disclosed are compounds and compositions that modulate cannabinoid receptors, methods of modulating cannabinoid receptors, and methods of treating various disorders related to the modulation of cannabinoid receptors. This disclosure is directed to methods of treating cannabinoid dependence, neuropathy, inflammation, glaucoma, a neurodegenerative disorder, a motor function disorder, a gastrointestinal disorder, hypothermia, emesis, loss of appetite, or anorexia associated with AIDS.

The present invention discloses a method of treating an individual having irritable bowel syndrome or a related disorder, comprising the step of administering to said individual a pharmacologically effective dose of a luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects. Further provided is a method of inhibiting the onset of symptoms of irritable bowel syndrome or a related disorder in an individual in need of such treatment, comprising the step of administering to the individual a prophylactically effective dose of a luminally active anti-inflammatory or immunosuppressive compound with minimal or no systemic side effects.

The present invention provides compositions and methods for preventing and treating gastrointestinal disorders by administering to a subject an effective amount of secretin either alone or in combination with an effective amount of oxytocin. The invention also provides compositions and methods for preventing and treating central nervous system disorders by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. The invention further provides compositions and methods for treating and preventing a variety of autoimmune diseases by administering to a subject an effective amount of secretin in combination with an effective amount of oxytocin. Additionally, the invention provides compositions and methods for preventing and treating pain by administering to a subject using a combination of an effective amount of secretin and an effective amount of oxytocin. The invention also provides kits for use in treating and / or preventing gastrointestinal disorders, central nervous system disorders, autoimmune diseases and pain comprising a combination of secretin and oxytocin.

Compounds of Formula (I):or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

The present invention relates generally to medicine. More specifically the invention relates to the use of synergistic probiotic bacteria as intervention for health. In particular, the present invention provides a strain of Faecalibacterium prausnitzii and a bacterial strain which has one or more of the characteristics of: (i) being acetate producing, (ii) being lactate consuming and (iii) having the ability to be an electron acceptor, for use in the treatment or prevention of a disease associated with reduced butyrate levels or a disease associated with reduced or low numbers of Faecalibacterium prausnitzii bacteria.

Particle or hadron therapy is used on abnormal tissue using carbon atoms, protons, or helium atoms run through a linear accelerator and then directed at the target in the body. This can be used to treat, for example, atrial fibrillation, ventricular tachycardia, hypertension, seizures, gastrointestinal maladies, etc. Contouring and gating may be used to account for cardiac and respiratory motion, helping reduce collateral damage.

A strain of Lactobacillus gasseri KBL697 and the use thereof are described. The strain of Lactobacillus gasseri KBL697 (Accession No. KCTC 13520BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects and a therapeutic effect for intestinal diseases such as irritable bowel syndrome and colitis. Thus, the single strain alone can achieve all the purposes of alleviating allergic diseases and inflammatory diseases and improving intestinal health, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.